cprx news - Search News

CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva

Catalyst stock gains 17% as it settles Firdapse patent litigation with Teva protecting the drug's exclusivity in the United States till Feb. 25, 2035.

Hosted on MSN · 2d

Catalyst stock climbs 15% on Firdapse litigation settlement

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock jumped 15% Wednesday on news the company had reached an agreement with Teva (TEVA) that would delay the launch of a generic version of its drug Firdapse until at least 2035.

Business Insider · 2d

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases,

MarketWatch · 2d

Catalyst Pharmaceuticals Jumps 14% on Firdapse Settlement With Teva

Shares of Catalyst Pharmaceuticals rose as the company reached a settlement agreement with Teva Pharmaceuticals related to Teva's plans for a generic version of Firdapse 10 mg tablets. Catalyst stock was recently at $22.

Zacks.com on MSN1d

Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?

Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer

Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

Hosted on MSN1d

Here's Why Momentum in Catalyst (CPRX) Should Keep going

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Benzinga.com1d

Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Quotes, Forecast and News Summary

Catalyst Rises as Q2 Earnings & Revenues Beat Estimates Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) reported adjusted earnings of 56 cents per share for the second quarter of 2024, beating the ...

Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...

bovnews1d

Analysts Predict a $35 Target for Catalyst Pharmaceuticals Inc (CPRX) Stock—What Could Drive It There?

Stephens has recently initiated Catalyst Pharmaceuticals Inc (CPRX) stock to Overweight rating, as announced on November 18, 2024, according to Finviz. Earlier, on March 14, 2024, Citigroup had ...

Catalyst Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Shares of Catalyst Pharmaceuticals Inc. CPRX slipped 3.27% to $19.53 Tuesday, on what proved to be an all-around rough ...

news.stocktradersdaily6d

(CPRX) Long Term Investment Analysis

Check the time stamp on this data. Updated AI-Generated Signals for Catalyst Pharmaceuticals Inc. (CPRX) available here: CPRX.

Catalyst Pharmaceuticals Secures Patent Victory: Analyst Reaffirms Buy Rating with 58.7% Upside Potential

Citi analyst Samantha Semenkow has maintained their bullish stance on CPRX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Catalyst Pharmaceuticals Inc. closed $2.96 short of its 52-week high ($24.27), which the company achieved on November 8th.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Related topics